ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,702.55
-0.19%
Dow Jones
42,063.36
0.09%
US Dollar vs MXN
19.4148
0.00%
Brent Oil
74.135
0.00%
Bitcoin
62,998.14
-0.33%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Noticias

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AZN
FechaHoraFuenteTítuloSímboloCompañía
20/09/202415:34Business WireFLUMIST approved for self-administration in the USNASDAQ:AZNAstraZeneca PLC
18/09/202406:00Business WireFASENRA approved in the US for eosinophilic granulomatosis with polyangiitisNASDAQ:AZNAstraZeneca PLC
17/09/202410:22GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:AZNAstraZeneca PLC
16/09/202406:00Business WireIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trialNASDAQ:AZNAstraZeneca PLC
15/09/202409:30Business WireIMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
13/09/202409:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastasesNASDAQ:AZNAstraZeneca PLC
10/09/202409:28PR Newswire (US)SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy TestingNASDAQ:AZNAstraZeneca PLC
10/09/202405:02IH Market NewsApple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%NASDAQ:AZNAstraZeneca PLC
09/09/202412:50Business WireDatopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
08/09/202411:25Business WireNovel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
05/09/202405:11IH Market NewsQualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual ListingNASDAQ:AZNAstraZeneca PLC
03/09/202406:00Business WireAstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024NASDAQ:AZNAstraZeneca PLC
23/08/202407:20IH Market NewsCruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%NASDAQ:AZNAstraZeneca PLC
16/08/202406:00Business WireIMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgeryNASDAQ:AZNAstraZeneca PLC
16/08/202405:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
15/08/202406:00Business WireIMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the USNASDAQ:AZNAstraZeneca PLC
30/07/202405:00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNASDAQ:AZNAstraZeneca PLC
29/07/202406:00Business WireFixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trialNASDAQ:AZNAstraZeneca PLC
25/07/202406:00Business WireAstraZeneca’s H1 and Q2 2024 Financial ResultsNASDAQ:AZNAstraZeneca PLC
25/07/202405:21IH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNASDAQ:AZNAstraZeneca PLC
25/07/202405:19IH Market NewsEarnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%NASDAQ:AZNAstraZeneca PLC
23/07/202406:00PR Newswire (Canada)Voydeya est approuvé au Canada à titre de traitement d'appoint au ravulizumab ou à l'éculizumab chez les adultes atteints d'une maladie rare, appelée HPN, qui présentent une anémie hémolytique résiduelle attribuable à une hémolyse extravasculairNASDAQ:AZNAstraZeneca PLC
23/07/202406:00PR Newswire (Canada)Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysisNASDAQ:AZNAstraZeneca PLC
25/06/202406:00Business WireIMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
17/06/202406:00Business WireIMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancerNASDAQ:AZNAstraZeneca PLC
16/06/202406:00Business WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
12/06/202416:35Business WireFARXIGA approved in the US for the treatment of pediatric type-2 diabetesNASDAQ:AZNAstraZeneca PLC
10/06/202406:00Business WireTAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancerNASDAQ:AZNAstraZeneca PLC
06/06/202406:00PR Newswire (US)I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerNASDAQ:AZNAstraZeneca PLC
04/06/202409:02Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Su Consulta Reciente

NYSE
VZ
Verizon Communications
NASDAQ
NVDA
NVIDIA
AMEX
SPY
SPDR S&P 500
COIN
XRPUSD
Ripple
NASDAQ
MSFT
Microsoft
USOTC
BASFY
BASF (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDMXN
US Dollar vs MXN
COIN
SOLUSD
Solana
USOTC
ADDYY
Adidas (QX)
CCOM
OILBRENT
Brent Oil
NYSE
MCD
McDonalds
NYSE
CVX
Chevron
NYSE
NKE
Nike
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados